This suggests loss-of-function is unlikely to explain PD pathology or etiology, and that LRRK2 may itself be a safe and attractive therapeutic target if ablated specifically within the CNS to avoid peripheral tissue damage. Here, LRRK2 is linked to Parkinson disease.